Why do you think that? The two topics being presented by doctors who have previously represented AMRN clinical trial research are pretty valid ones given R-IT results. Not sure I like throwing the focus back on TGs instead of outcomes, but clinicians do need some kind of guidance on how to identify and treat high risk patients with elevated TGs. For instance, the first presentation will likely identify when high TGs indicate elevated CVD risk and when they don't - they could present me as a case subject, LOL - my TGs are embarrassingly high despite being on V (NAFLD), but my LDL-C is 90 (no statin) and I have no other traditional risk factors. They had gotten as low as 173 after starting V, but since late 2017 they started climbing and haven't come back down, actually kept going up - something physiological must have changed as I got older - my asthma got much worse too.
SESSION 2: WHEN LDL-C REDUCTION IS NOT ENOUGH: TACKLING TRIGLYCERIDES TO REDUCE ASCVD-RELATED EVENTS
• Hypertriglyceridemia: Identifying the High-Risk Patient
Michael Miller, MD, FACC, FAHA (15 minutes)
• Recent Outcome Trials for Triglyceride Lowering Agents: Current and Emerging Data
Christie M. Ballantyne, MD, FACC, FACP, FNLA (15 minutes)
• Interactive Table Discussion (60 minutes)
• Report Back to Full Group (30 minutes)